Search

Your search keyword '"Pados, G"' showing total 222 results
Start Over Author "Pados, G"
222 results on '"Pados, G"'

9. 491 The impact of ERAS in cytoreduction for advanced ovarian cancer

Author

Tsolakidis, D, primary, Zouzoulas, D, additional, Markopoulou, E, additional, Chatzistamatiou, K, additional, Zymperdikas, C, additional, Anthoulakis, C, additional, Mikos, T, additional, Zepeiridis, L, additional, Mpili, E, additional, Pados, G, additional, Papanikolaou, A, additional, and Grimbizis, G, additional

Published
2021
Full Text
View/download PDF

10. 480 Comparison of primary vs. interval debunking surgery in patients with ovarian cancer managed with ERAS protocol

Author

Zouzoulas, D, primary, Tsolakidis, D, additional, Zymperdikas, C, additional, Chatzistamatiou, K, additional, Anthoulakis, C, additional, Markopoulou, E, additional, Ioannidou, P, additional, Korvesi, V, additional, Mikos, T, additional, Theodoridis, T, additional, Mpili, E, additional, Pados, G, additional, and Grimbizis, G, additional

Published
2021
Full Text
View/download PDF

12. A European survey on the conservative surgical management of endometriotic cysts on behalf of the European Society for Gynaecological Endoscopy (ESGE) Special Interest Group (SIG) on Endometriosis

Author

Pados G, Daniilidis A, Joerg Keckstein, Papandreou P, and Gordts S

Subjects
cystectomy, Short Communication, excision, Endometrioma, stripping, laparoscopic surgery, ablation
Abstract

The mainstay of endometrioma management, when treatment is required, is surgical. Although laparoscopy is considered to be the gold standard for endometriosis surgery, there is no clarity on the preferred laparoscopic technique, which may depend on whether the primary goalis treatment of infertility or pelvic pain, prevention of recurrence or preservation of ovarian reserve. The aim of this survey to assess the surgical practice of the members of the European Society for Gynaecological Endoscopy (ESGE) on the conservative management of endometiotic cysts in women of reproductive age. The current survey showed that practice for the conservative management of endometriotic cysts was that laparoscopy accounted for 84.9% of the cases, expectant management for 12.1%, and laparotomy for 3%. The preferred surgical approach was cystectomy in 69% of the cases, while the parameters that determined the preferred surgical method were the diameter of the cyst (62%) and the bilaterality or non-location (53%). The type of energy used was in most cases bipolar (83%), 71.4% of surgeons did not reconstitute the ovary and 41% of responses included the administration of adhesion barrier agents. The primary surgical end-point was ovarian reserve (50%), which was tested preoperatively in 51.8%, mainly with an anti-mullerian hormone. In case of an incidentally deep-infiltrating endometriosis, 55.4% of the responses included concomitant treatment thereof, while 71% of the participants considered that a “pelvic surgeon”, who could more effectively treat co- existing pelvic and intestinal disease, should be the ideal one to effectively manage endometriosis. The majority of participants (74%) in this survey consider that there is insufficient scientific evidence regarding the conservative management of endometriotic cysts. The treatment of ovarian endometrioma should be individualised, taking into consideration not only the relief of symptoms, pregnancy rates or recurrence rates, but also ovarian function and reserve after surgery.

Published
2020

15. Gynaecological endoscopic evaluation of 4% icodextrin solution: a European, multicentre, double-blind, randomized study of the efficacy and safety in the reduction of de novo adhesions after laparoscopic gynaecological surgery

Author

Trew, G., Pistofidis, G., Pados, G., Lower, A., Mettler, L., Wallwiener, D., Korell, M., Pouly, J.-L., Coccia, M.E., Audebert, A., Nappi, C., Schmidt, E., McVeigh, E., Landi, S., Degueldre, M., Konincxk, P., Rimbach, S., Chapron, C., Dallay, D., Röemer, T., McConnachie, A., Ford, I., Crowe, A., Knight, A., diZerega, G., and DeWilde, R.

Published
2011
Full Text
View/download PDF

18. TIG welding of in-situproduced syntactic metal foam-filled tubes

Author

Kemény, A, Pados, G, Májlinger, K, and Orbulov, I N

Abstract

Aluminium matrix double composites were produced via an in-situpressure infiltration method. AlSi12 alloy matrix with densely packed lightweight expanded clay aggregate particle-filled foam was produced in-situwithin AlMgSi0.5 alloy tubes. The attainable size of such double composites is limited; therefore, joining them is required to create larger parts. For the joining of these double composites, the applicability of tungsten inert gas (TIG) welding was tested. TIG welding was found to be applicable to join such composites. Metallurgically sound welded joints were produced. Nevertheless, the TIG welding of metal foam-filled tubes is very challenging and needs experienced welding personnel, and the weld bead was a bulk material, not a foam anymore.

Published
2024
Full Text
View/download PDF

21. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry

Author

Rogers‑Broadway, KR, Kumar, J, Sisu, C, Wander, G, Mazey, E, Jeyaneethi, J, Pados, G, Tsolakidis, D, Klonos, E, Grunt, T, Hall, M, Chatterjee, J, Karteris, E, GRACE, Department of Gynaecological Oncology, The Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, and Cancer Treatment and ResearchTrust (CTRT), Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK.

Subjects
Ovarian Neoplasms, endometriosis, endocrine system diseases, TOR Serine-Threonine Kinases, Articles, Mechanistic Target of Rapamycin Complex 2, Mechanistic Target of Rapamycin Complex 1, female genital diseases and pregnancy complications, ovarian cancer, Cell Line, Tumor, mTOR, Humans, Female, Protein Kinase Inhibitors, rapalogues, Signal Transduction
Abstract

© Rogers‑Broadway et al. Endometriosis is a well-known risk factor for ovarian cancer. The genetic changes that characterise endometriosis are poorly understood; however, the mechanistic target of rapamycin (mTOR) pathway is involved. In this study, we investigated the expression of key mTOR components in endometriosis and the effects of rapalogues using an endometrioid ovarian carcinoma cell line (MdAH 2774) as an in vitro model. Gene expression of mTOR, dEPTOR, Rictor and Raptor was assessed by qPcR in 24 endometriosis patients and in silico in ovarian cancer patients. Furthermore, the effects of Rapamycin, Everolimus, deforolimus, Temsirolimus, Resveratrol, and BEZ235 (dactolisib, a dual kinase inhibitor) on mTOR signalling components was assessed. mTOR showed a significant increase in the expression in endometriosis and ovarian endometrioid adenocarcinoma patients compared to non-affected controls. dEPTOR, an inhibitor of mTOR, was downregulated in the advanced stages of ovarian cancer (III and IV) compared to earlier stages (I and II). Treatment of MdAH-2774 cells with the mTOR inhibitors resulted in the significant upregulation of dEPTOR mRNA, whereas treatment with rapamycin and BEZ-235 (100 nM) resulted in downregulation of the mTOR protein expression after 48 h of treatment. None of the treat ments resulted in translocation of mTOR from cytoplasm to nucleus. Upregulation of dEPTOR is a positive prognostic marker in ovarian cancer and is increased in response to mTOR pathway inhibition suggesting that it functions as a tumour suppressor gene in endometrioid ovarian carcinoma. collectively, our data suggest the mTOR pathway as a potential connection between endometriosis and ovarian cancer and may be a potential target in the treatment of both conditions.

Published
2018

23. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

Author

James, Wp, Caterson, Id, Coutinho, W, Finer, N, VAN GAAL LF, Maggioni, Ap, TORP-PEDERSEN, C, Sharma, Am, Shepherd, Gm, Rode, Ra, Renz, Cl, Van Gaal LF, Torp-Pedersen, C, Pepine, C, Pocock, S, Drexler, H, Swedberg, K, Sleight, P, Armstrong, P, Kerr, D, Dagenais, G, Brophy, J, Avezum, A, Bogaty, P, Fabbri, G, Galli, M, Hildebrandt, P, Mann, J, Ostergren, J, Sherman, D, Zannad, F, Colquhoun, D, Hollanders, G, e Forti A, Costa, Cifkova, R, Toubro, S, Ziegler, O, Scherbaum, Wa, Jordan, J, Halmy, L, Ferrannini, E, Santini, F, Gonzalez, C, Narkiewicz, K, Hancu, N, Payer, J, Pascual, J, Wilding, J, Campbell, L, Carey, D, Gerstman, M, Karrasch, J, Lefkovits, J, Marks, J, Marks, S, Moses, R, Phillips, P, Proietto, J, Roberts, D, Roberts-Thomson, P, Shaw, J, Simpson, R, Singh, B, Singleton Jeffries, W, Stuckey, B, Boland, J, Brohet, C, Coucke, F, Dendale, P, Jouret, G, Kolanowski, J, Kutnowski, M, Martens, F, Muls, E, Peiffer, F, Penninckx, H, Scheen, A, Schoors, D, Vaerenberg, M, Van Cleemput, J, Van Crombrugge, P, Van Kuyk, M, Verhaegen, A, Wollaert, B, de Albuquerque DC, Appolinario, J, de Godoy Matos AF, Gross, Jl, Halpern, A, Kerr Saraiva JF, Milagres, R, Repetto, G, Suplicy, Hl, Zanella, Mt, Bednarova, J, Cepelak, V, Cerny, P, Hainer, V, Havranek, P, Homza, M, Jansa, P, Karlicek, M, Kolesar, J, Kotik, I, Kucera, D, Kuchar, J, Kunc, M, Kvapil, M, Linhart, A, Machova, V, Matuska, J, Oral, I, Pavlas, J, Pesatova, S, Povolny, J, Semrad, B, Smetana, K, Soucek, M, Svacina, S, Tesinsky, P, Urbanek, R, Wasserburger, B, Zachoval, R, Zahumensky, E, Zidkova, E, Astrup, A, Dominguez, H, Faber, J, Hilderbrant, P, Kober, L, Perrild, H, Richelsen, B, Sogaard, P, Svendsen, Ol, Urhammer, S, Archambeaud, F, Basdevant, A, Borys, Jm, Bringer, J, Brunetiere, C, Charpentier, G, Cocaul-André, M, Dabadie, H, Dubreuil, A, Estour, B, Gautier, Jf, Gibault, T, Halimi, S, Hespel, Jp, Issa Sayegh, M, Krempf, M, Laville, M, Lecerf, Jm, Louvet, Jp, Penfornis, A, Ritz, P, Schlienger, Jl, Schmitt, B, Valensi, P, Baar, M, Beermann, J, Bock, M, Boenner, G, Dammann, Hg, Diehm, C, Ditschuneit, H, Gadow, J, Gehlhar, S, Gessner, S, Guthersohn, A, Hamann, A, Hanefeld, M, Hasenfuss, G, Herzner, A, Heun, Kc, Heufelder, Ae, Hohensee, H, Jacob, S, Krings, P, Krätzig, B, Krosse, B, Lehmann, Rt, Mindt-Prüfert, S, Maisch, B, Pfeiffer, Af, Richard, F, Rose, B, Schmidt, E, Scholze, J, Schreckenberg, A, Stuebler, P, Walter, J, Wirth, A, Wunderlich, J, Abraham, G, Altorjay, A, Augusztin, G, Csaszar, A, Czuriga, I, Dinnyes, J, Gero, L, Gyimesi, A, Janosi, A, Kovacs, I, Liziczai, I, Majtenyi, A, Medvegy, M, Nadhazi, Z, Pados, G, Polak, G, Ronaszeki, A, Sido, Z, Simon, K, Anzà, C, Bevilacqua, M, Bosello, O, Chiariello, M, Cordera, R, Ferrari, E, Frittitta, L, Giorgino, R, Liuzzi, A, Malinverni, C, Di Mario, U, Melchionda, N, Occhi, G, Perticone, F, Pinchera, A, Pinelli, G, Rovera, G, Santeusanio, F, Urbinati, S, Alpizar-Salazar, M, Carrillo-Ortega, E, Fanghanel Salmon, G, Laviada-Molina, Ha, Madero, Ma, Rodriguez, G, Saldate, C, Sanchez-Castillo, Cp, Violante, Rm, Wacher, N, Zayas-Jaime, Fj, Zuniga-Guajardo, S, Adamiec, R, Banasiak, W, Chrusciel, P, Derlaga, B, Gebala, A, Gessek, J, Janik, K, Janion, M, Kalina, Z, Kozlowski, A, Kusnierz, B, Majcher, Z, Miekus, P, Niegowska, J, Okopien, B, Ostrowska, L, Pasowicz, M, Piepiorka, M, Pluta, W, Polaszewska-Muszynska, M, Ponikowski, P, Pupek-Musialik, D, Sawicki, A, Sobocik, H, Stankiewicz, A, Szpajer, M, Trojnar, R, Tykarski, A, Wrabec, K, Wyrzkowski, B, Zahorska-Markiewicz, B, Zalewski, M, Carrageta, M, Mendes Pedro MM, Parente Martins LM, dos Santos, L, Babes, A, Creteanu, G, Dan, Ga, Dragulescu, Si, Graur, M, Tirgoviste, Ci, Morosanu, M, Mota, M, Paveliu, Fs, Radoi, M, Ranetti, A, Totoian, I, Andre, I, Bugan, V, Cencarik, J, Csala, L, Farsky, S, Gonsorcik, J, Kamensky, G, Kmec, J, Krahulec, B, Kurian, R, Macek, V, Majercak, I, Micko, K, Mokan, M, Riecansky, I, Sojka, G, Uhliar, R, Urgeova, L, Vancik, J, Baro, Fm, Barrios Merino, A, Borras, Jl, Caixas, A, Cuatrecasas Cambra, G, Dominguez Escribano JR, Duran Garcia, S, Escobar-Jimenez, L, Esteva de Antonio, I, Formiguera Sala, X, Garcia-Luna, Pp, Garcia Robles, R, Gonzalez Albarran, O, Hernandez-Mijares, A, Martin Hidalgo, A, Masmiquel Comas, L, Morales Perez, F, Moreno Esteban, B, Pascual Izuel JM, Redon Mas, J, Ricart, W, Rubio, Ma, Ruilope, Lm, Salas-Salvado, J, Terroba Larumbe, M, Tinahones, F, de la Torre Casares ML, Vidal Cortada, J, Zuniga-Perez Lemaur, M, Abdulhakim, Ee, Adler, A, Barnett, Ah, Bodmer, C, Campbell, Iw, Chowdhury, T, Cleland, J, Cook, Rc, Dinneen, S, Donnachie, H, Haslam, Dw, Hillis, Gs, Horne, M, Howarth, Dj, Hughes, E, Jackson, S, Jones, Sc, Jones, Th, Kumar, S, Lean, M, Maroni, J, Mcinnes, G, Middleton, A, Morris, A, Newcombe, G, O'Kane, Kp, Pavel, Ic, Pawa, R, Perry, C, Pitts, C, Raja, A, Reckless, J, Robinson, J, Sarmiento, R, Soo, Sc, Taylor, S, Thomas, Ho, Thomson, Ma, and Wilkins, M.

Subjects
Male, medicine.medical_specialty, Myocardial Infarction, Blood Pressure, Kaplan-Meier Estimate, Type 2 diabetes, Klinikai orvostudományok, Placebo, law.invention, Double-Blind Method, Randomized controlled trial, Weight loss, law, Internal medicine, Appetite Depressants, medicine, Humans, Obesity, Myocardial infarction, Stroke, Aged, business.industry, Hazard ratio, Orvostudományok, General Medicine, Middle Aged, Overweight, medicine.disease, Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Cardiology, Female, Human medicine, medicine.symptom, business, Cyclobutanes, Sibutramine, medicine.drug
Abstract

Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)

Published
2010
Full Text
View/download PDF

24. Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro

Author

Rogers-Broadway, KR, Chudasama, D, Pados, G, Tsolakidis, D, Goumenou, A, Hall, M, and Karteris, E

Subjects
Rapalogues, endocrine system diseases, Ovarian cancer, Resveratrol, S6K
Abstract

Ovarian cancer is the second most common gynaecological malignancy and was diagnosed in over 7,000 women in 2011 in the UK. There are currently no reliable biomarkers available for use in a regular screening assay for ovarian cancer and due to characteristic late presentation (78% in stages III and IV) ovarian cancer has a low survival rate (35% after 10 years). The mTOR pathway is a central regulator of growth, proliferation, apoptosis and angiogenesis; providing balance between available resources such as amino acids and growth factors, and stresses such as hypoxia, to control cellular behaviour accordingly. Emerging data links mTOR with the aetiopathogenesis of ovarian cancer. We hypothesised that mTOR inhibitors could play a therapeutic role in ovarian cancer treatment. In this study we began by validating the expression of four main mTOR pathway components, mTOR, DEPTOR, rictor and raptor, at gene and protein level in in vitro models of endometrioid (MDAH2774) and clear cell (SKOV3) ovarian cancer using qPCR and ImageStream technology. Using a wound healing assay we show that inhibition of the mTOR pathway using rapamycin, rapalogues, resveratrol and NVP BEZ-235 induces a cytostatic and not cytotoxic response up to 18 h in these cell lines. We extended these findings up to 72 h with a proliferation assay and show that the effects of inhibition of the mTOR pathway are primarily mediated by the dephosphorylation of p70S6 kinase. We show that mTOR inhibition does not involve alteration of mTOR pathway components or induce caspase 9 cleavage. Preclinical studies including ovarian tissue of ovarian cancer patients, unaffected controls and patients with unrelated gynaecological conditions show that DEPTOR is reliably upregulated in ovarian cancer.

Published
2016

28. GnRH-agonist versus GnRH-antagonist IVF cycles:is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study

Author

Papanikolaou, E G, Pados, G, Grimbizis, G, Bili, E, Kyriazi, L, Polyzos, N P, Humaidan, P, Tournaye, H, Tarlatzis, B, and Al Humaidan, Peter Samir Heskjær

Subjects
Agonist, Adult, endocrine system, medicine.medical_specialty, medicine.drug_class, media_common.quotation_subject, Gonadotropin-releasing hormone, Fertilization in Vitro, Biology, Buserelin, Chorionic Gonadotropin, Gonadotropin-releasing hormone antagonist, Gonadotropin-Releasing Hormone, Pregnancy, Internal medicine, Follicular phase, medicine, Humans, Prospective Studies, Sperm Injections, Intracytoplasmic, Ganirelix, Ovulation, Progesterone, media_common, Rehabilitation, Antagonist, Pregnancy Outcome, Obstetrics and Gynecology, Embryo Transfer, Endocrinology, Reproductive Medicine, Female, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

BACKGROUND: In view of the current debate concerning possible differences in efficacy between the two GnRH analogues used in IVF stimulated cycles, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH antagonist is used as compared with GnRH agonist, and if so, to what extent the progesterone rise affects the probability of pregnancy.METHODS: Overall 190 patients were randomized: 94 in the GnRH-agonist group and 96 in the GnRH-antagonist group. The GnRH-agonist long protocol started on Day 21 of the preceding cycle with intranasal buserelin (600 mg per day). The GnRH-antagonist protocol started on Day 6 of the stimulation with ganirelix or cetrorelix (each 0.25 mg). All blood samples were analysed with the Elecsys analyzer. An intention-to-treat analysis was applied.RESULTS: A progesterone rise >1.5 ng/ml was noticed in 23.0% of the antagonist group, comparable with 24.1% incidence within the agonist group. Per patient randomized, delivery rates were also comparable: 28.1% in the antagonist group and 24.5% in the agonist group (odds ratio = 1.21, 95% confidence interval: 0.63-2.31, P= 0.56). However, there was a reduction in delivery rates when progesterone exceeded the threshold of 1.5 ng/ml, both in the agonist group (9.5 versus 31.8%, P= 0.03) and in the antagonist group (14.3 versus 34.3%, P= 0.07).CONCLUSIONS: Although the incidence of a progesterone rise was similar between the two analogues, our findings reconfirm previous observations that insufficient progesterone control (>1.5 ng/ml) on the day of ovulation triggering is related to poor delivery rates in both protocols. The current study has shown that the reproductive outcomes with the two GnRH analogues are comparable. Possible modes of action to circumvent late follicular progesterone rise should be explored.TRIAL REGISTRATION NUMBER: NCT01191710.

Published
2012
Full Text
View/download PDF

29. GNRH-agonist versus GNRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering?

Author

Papanikolaou, Evangelos, Pados, G., Grimbizis, Grigorius F, Bili, E, Kyriazi, L, Polyzos, Nikolaos, Humaidan, Peter, Tournaye, Herman, Tarlatzis, Basil, Department of Embryology and Genetics, Surgical clinical sciences, and Faculty of Medicine and Pharmacy

Abstract

BACKGROUNDIn view of the current debate concerning possible differences in efficacy between the two GnRH analogues used in IVF stimulated cycles, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH antagonist is used as compared with GnRH agonist, and if so, to what extent the progesterone rise affects the probability of pregnancy.METHODSOverall 190 patients were randomized: 94 in the GnRH-agonist group and 96 in the GnRH-antagonist group. The GnRH-agonist long protocol started on Day 21 of the preceding cycle with intranasal buserelin (600 mg per day). The GnRH-antagonist protocol started on Day 6 of the stimulation with ganirelix or cetrorelix (each 0.25 mg). All blood samples were analysed with the Elecsys analyzer. An intention-to-treat analysis was applied.RESULTSA progesterone rise >1.5 ng/ml was noticed in 23.0% of the antagonist group, comparable with 24.1% incidence within the agonist group. Per patient randomized, delivery rates were also comparable: 28.1% in the antagonist group and 24.5% in the agonist group (odds ratio = 1.21, 95% confidence interval: 0.63-2.31, P= 0.56). However, there was a reduction in delivery rates when progesterone exceeded the threshold of 1.5 ng/ml, both in the agonist group (9.5 versus 31.8%, P= 0.03) and in the antagonist group (14.3 versus 34.3%, P= 0.07).CONCLUSIONSAlthough the incidence of a progesterone rise was similar between the two analogues, our findings reconfirm previous observations that insufficient progesterone control (>1.5 ng/ml) on the day of ovulation triggering is related to poor delivery rates in both protocols. The current study has shown that the reproductive outcomes with the two GnRH analogues are comparable. Possible modes of action to circumvent late follicular progesterone rise should be explored.Trial registration number: NCT01191710.

Published
2012

35. FEMALE (IN)FERTILITY

Author

Kanta Goswami, S., primary, Banerjee, S., additional, Saha, P., additional, Chakraborty, P., additional, Kabir, S. N., additional, Karimzadeh, M. A., additional, Mohammadian, F., additional, Mashayekhy, M., additional, Saldeen, P., additional, Kallen, K., additional, Karlstrom, P. O., additional, Rodrigues-Wallberg, K. A., additional, Salerno, A., additional, Nazzaro, A., additional, Di Iorio, L., additional, Marino, S., additional, Granato, C., additional, Landino, G., additional, Pastore, E., additional, Ghoshdastidar, B., additional, Chakraborty, C., additional, Ghoshdastidar, B. N., additional, Ghoshdastidar, S., additional, Partsinevelos, G. A., additional, Papamentzelopoulou, M., additional, Mavrogianni, D., additional, Marinopoulos, S., additional, Dinopoulou, V., additional, Theofanakis, C., additional, Anagnostou, E., additional, Loutradis, D., additional, Franz, C., additional, Nieuwland, R., additional, Montag, M., additional, Boing, A., additional, Rosner, S., additional, Germeyer, A., additional, Strowitzki, T., additional, Toth, B., additional, Mohamed, M., additional, Vlismas, A., additional, Sabatini, L., additional, Caragia, A., additional, Collins, B., additional, Leach, A., additional, Zosmer, A., additional, Al-Shawaf, T., additional, Beyhan, Z., additional, Fisch, J. D., additional, Danner, C., additional, Keskintepe, L., additional, Aydin, Y., additional, Ayca, P., additional, Oge, T., additional, Hassa, H., additional, Papanikolaou, E., additional, Pados, G., additional, Grimbizis, G., additional, Bili, H., additional, Karastefanou, K., additional, Fatemi, H., additional, Kyrou, D., additional, Humaidan, P., additional, Tarlatzis, B., additional, Gungor, F., additional, Karamustafaoglu, B., additional, Iyibozkurt, A. C., additional, Ozsurmeli, M., additional, Bastu, E., additional, Buyru, F., additional, Di Emidio, G., additional, Vitti, M., additional, Mancini, A., additional, Baldassarra, T., additional, D'Alessandro, A. M., additional, Polsinelli, F., additional, Tatone, C., additional, Leperlier, F., additional, Lammers, J., additional, Dessolle, L., additional, Lattes, S., additional, Barriere, P., additional, Freour, T., additional, Elodie, P., additional, Assou, S., additional, Van den Abbeel, E., additional, Arce, J. C., additional, Hamamah, S., additional, Dechaud, H., additional, Haouzi, D., additional, Tiplady, S., additional, Johnson, S., additional, Jones, G., additional, Ledger, W., additional, Eizadyar, N., additional, Ahmad Nia, S., additional, Seyed Mirzaie, M., additional, Azin, S. A., additional, Yazdani Safa, M., additional, Onaran, Y., additional, Iltemir Duvan, C., additional, Keskin, E., additional, Ayrim, A., additional, Kafali, H., additional, Kadioglu, N., additional, Guler, B., additional, Var, T., additional, Cicek, M. N., additional, Batioglu, A. S., additional, Lichtblau, I., additional, Olivennes, F., additional, de Mouzon, J., additional, Dumont, M., additional, Junca, A. M., additional, Cohen-Bacrie, M., additional, Hazout, A., additional, Belloc, S., additional, Cohen-Bacrie, P., additional, Allegra, A., additional, Marino, A., additional, Sammartano, F., additional, Coffaro, F., additional, Scaglione, P., additional, Gullo, S., additional, Volpes, A., additional, Prisant, N., additional, Saare, M., additional, Vaidla, K., additional, Salumets, A., additional, Peters, M., additional, Jindal, U. N., additional, Thakur, M., additional, Shvell, V., additional, Diamond, M. P., additional, Awonuga, A. O., additional, Veljkovic, M., additional, Macanovic, B., additional, Milacic, I., additional, Borogovac, D., additional, Arsic, B., additional, Pavlovic, D., additional, Lekic, D., additional, Bojovic Jovic, D., additional, Garalejic, E., additional, Jayaprakasan, K., additional, Eljabu, H., additional, Hopkisson, J., additional, Campbell, B., additional, Raine-Fenning, N., additional, Kop, P., additional, van Wely, M., additional, Mol, B. W., additional, Melker, A. A., additional, Janssens, P. M. W., additional, Nap, A., additional, Arends, B., additional, Roovers, J. P. W. R., additional, Ruis, H., additional, Repping, S., additional, van der Veen, F., additional, Mochtar, M. H., additional, Sargin, A., additional, Yilmaz, N., additional, Gulerman, C., additional, Guven, A., additional, Polat, B., additional, Ozel, M., additional, Bardakci, Y., additional, Vidal, C., additional, Giles, J., additional, Remohi, J., additional, Pellicer, A., additional, Garrido, N., additional, Javdani, M., additional, Fallahzadeh, H., additional, Davar, R., additional, Sheibani, H., additional, Leary, C., additional, Killick, S., additional, Sturmey, R. G., additional, Kim, S. G., additional, Lee, K. H., additional, Park, I. H., additional, Sun, H. G., additional, Lee, J. H., additional, Kim, Y. Y., additional, Choi, E. M., additional, Van Loendersloot, L. L., additional, Van Wely, M., additional, Bossuyt, P. M. M., additional, Van Der Veen, F., additional, Roychoudhury Sarkar, M., additional, Roy, D., additional, Sahu, R., additional, Bhattacharya, J., additional, Eguiluz Gutierrez- Barquin, I., additional, Sanchez Sanchez, V., additional, Torres Afonso, A., additional, Alvarez Sanchez, M., additional, De Leon Socorro, S., additional, Molina Cabrillana, J., additional, Seara Fernandez, S., additional, Garcia Hernandez, J. A., additional, Ozkan, Z. S., additional, Simsek, M., additional, Kumbak, B., additional, Atilgan, R., additional, Sapmaz, E., additional, Agirregoikoa, J. A., additional, DePablo, J. L., additional, Abanto, E., additional, Gonzalez, M., additional, Anarte, C., additional, Barrenetxea, G., additional, Aleyasin, A., additional, Mahdavi, A., additional, Agha Hosseini, M., additional, Safdarian, L., additional, Fallahi, P., additional, Bahmaee, F., additional, Sarikaya, E., additional, Segawa, T., additional, Teramoto, S., additional, Tsuchiyama, S., additional, Miyauchi, O., additional, Watanabe, Y., additional, Ohkubo, T., additional, Shozu, M., additional, Ishikawa, H., additional, Yelian, F., additional, Papaioannou, S., additional, Knowles, T., additional, Aslam, M., additional, Milnes, R., additional, Takashima, A., additional, Takeshita, N., additional, Kinoshita, T., additional, Chapman, M. G., additional, Kilani, S., additional, Dadras, N., additional, Parsanezhad, M. E., additional, Zolghadri, J., additional, Younesi, M., additional, Floehr, J., additional, Dietzel, E., additional, Wessling, J., additional, Neulen, J., additional, Rosing, B., additional, Tan, S., additional, Jahnen-Dechent, W., additional, Lee, K. S., additional, Joo, J. K., additional, Son, J. B., additional, Joo, B. S., additional, Risquez, F., additional, Confino, E., additional, Llavaneras, F., additional, Marval, I., additional, D'Ommar, G., additional, Gil, M., additional, Risquez, M., additional, Lozano, L., additional, Paublini, A., additional, Piras, M., additional, Risquez, A., additional, Prochazka, R., additional, Blaha, M., additional, Nemcova, L., additional, Weghofer, A., additional, Kim, A., additional, Barad, D. H., additional, Gleicher, N., additional, Kilic, Y., additional, Ergun, B., additional, Howard, B., additional, Weiss, H., additional, Doody, K., additional, Schafer, C., additional, Ensslen, S., additional, Denecke, B., additional, Veitinger, T., additional, Spehr, M., additional, Tropartz, T., additional, Tolba, R., additional, Egert, A., additional, Schorle, H., additional, Alanya, S., additional, and Yumru, H., additional

Published
2012
Full Text
View/download PDF

36. SELECTED ORAL COMMUNICATION SESSION, SESSION 02: EMBRYOLOGY - QUALITY AND DEVELOPMENT Monday 4 July 2011 10:00 - 11:30

Author

Ahlstrom, A., primary, Westin, C., additional, Wikland, M., additional, Hardarson, T., additional, Mitsoli, A., additional, Kolibianakis, E. M., additional, Loutradi, K., additional, Venetis, C. A., additional, Triantafilidis, S., additional, Makedos, A., additional, Chatzimeletiou, K., additional, Zepiridis, L., additional, Bili, H., additional, Pados, G., additional, Tzamtzoglou, A., additional, Tarlatzis, B. C., additional, Musters, A., additional, Wely van, M., additional, Verhoeve, H., additional, Repping, S., additional, Veen van der, F., additional, Mochtar, M. H., additional, Menezes, J., additional, Sjoblom, P., additional, Tristen, C., additional, Wramsby, H., additional, Ivec, M., additional, Kovacic, B., additional, Vlaisavljevic, V., additional, Ghoshdastidar, S., additional, Ghoshdastidar, B., additional, and Chakraborty, C., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results